Lopes, Renato D.Becker, Richard C.Garcia, DavidHylek, Elaine M.Granger, Christopher B.Lourenço, Dayse M.Nader, Helena B.Maffei, Francisco Humberto de Abreu [UNESP]Cesena, Fernando H.Y.Nicolau, José C.Timmerman, AriRocha, Ana T.Paiva, Edison F.Guimaraes, Helio P.Carvalho, Antonio C.D'Amico, Elbio A.Moreira-Filho, Carlos A.Aldrighi, José M.Lopes, Antonio C.2014-05-272014-05-272009-04-08Journal of Thrombosis and Thrombolysis, v. 28, n. 1, p. 106-116, 2009.0929-5305http://hdl.handle.net/11449/70983The importance of thrombosis and anticoagulation in clinical practice is rooted firmly in several fundamental constructs that can be applied both broadly and globally. Awareness and the appropriate use of anticoagulant therapy remain the keys to prevention and treatment. However, to assure maximal efficacy and safety, the clinician must, according to the available evidence, choose the right drug, at the right dose, for the right patient, under the right indication, and for the right duration of time. The first International Symposium of Thrombosis and Anticoagulation in Internal Medicine was a scientific program developed by clinicians for clinicians. The primary objective of the meeting was to educate, motivate and inspire internists, cardiologists and hematologists by convening national and international visionaries, thought-leaders and dedicated clinician-scientists in Sao Paulo, Brazil. This article is a focused summary of the symposium proceedings. © Springer Science+Business Media, LLC 2009.106-116engAnticoagulationInternal medicineThrombosisacetylsalicylic acidanticoagulant agentantithrombinantithrombocytic agentantivitamin Kapixabanazd 0837betrixabanblood clotting factor 10a inhibitorclopidogreldabigatrandalteparindu 176benoxaparinfibrinogen receptor antagonistfondaparinuxheparinhiruloglow molecular weight heparinnadroparinplaceboprasugrelpurinergic receptor blocking agentreviparinrivaroxabanstreptokinasethrombin inhibitortm 150unclassified drugunindexed drugwarfarinym 150acute coronary syndromeangina pectorisanticoagulant therapyanticoagulationatherogenesisbleedingBrazilcerebrovascular accidentclinical educationclinical trialdeep vein thrombosisdrug mechanismdrug metabolismembolismendothelial dysfunctionfibrin clotheart atrium fibrillationheart infarctionhemostasisheparin induced thrombocytopeniahumaninternal medicineinternational normalized ratiolow drug dosemalignant neoplastic diseasemedical societyorthopedic surgeryoxidative stresspharmacogenomicspractice guidelinepriority journalprosthetic valve thrombosisrecommended drug doserisk assessmentrisk benefit analysisrisk reductionST segment elevationsurgical risksymposiumthrombocyte functionthrombocytopeniathromboembolismthrombosisthrombosis preventionvalvular heart diseasevascular endotheliumvenous thromboembolismAnticoagulantsCongresses as TopicArtigo10.1007/s11239-009-0324-4Acesso restrito2-s2.0-67549087939